TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT00925652

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methotrexate

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methotrexate

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Lifestyle: Diet

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Lifestyle: Diet

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Lifestyle: Diet

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Lifestyle: Diet

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Lifestyle: Diet+Exercise

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Lifestyle: Diet+Exercise
Study: NCT03186989

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IONIS MAPTRx
Description: Part 1: IONIS MAPTRx is administered intrathecally at 4 week intervals over the course of a 13 week treatment period for dose levels A, B, C, and D.~Part 2: IONIS MAPTRx is administered intrathecally at quarterly intervals for 48 weeks.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: A placebo is administered intrathecally at 4 week intervals over the course of 13 weeks in Part 1. No placebo is given in Part 2.
Study: NCT03348098

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Apatinib
Description: 500 mg, po, qd. 12weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: drug: Paclitaxel ,80mg/m2, d1, Once a week , A total of 12 weeks; 3 weeks as a cycle
Study: NCT01116076

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Decision+ program (to improve optimal drug prescription for ARI)
Description: DECISION+ is a multifaceted intervention program that includes: On site course and Internet-based courses (2x120 min), reminders of expected behaviours and feedback.
Study: NCT02150070

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ASP2408
Description: Intravenous (IV) infusion and subcutaneous (SC) injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ASP2408
Description: Intravenous (IV) infusion and subcutaneous (SC) injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ASP2408
Description: Intravenous (IV) infusion and subcutaneous (SC) injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ASP2408
Description: Intravenous (IV) infusion and subcutaneous (SC) injection

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Intravenous (IV) infusion and Subcutaneous (SC) injection

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Intravenous (IV) infusion and Subcutaneous (SC) injection
Study: NCT00862459

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gadobutrol~0.03 mmol/kg BW (Gadavist, Gadovist, BAY86-4875)
Description: Participant received one dose of 0.03 mmol/kg BW of Gadobutrol. Gadobutrol was administered via a power injector at a rate of 5 mL/s followed by a 20 mL 0.9% saline flush at the same rate.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gadobutrol~0.1 mmol/kg BW (Gadavist, Gadovist, BAY86-4875)
Description: Participant received one dose of 0.1 mmol/kg BW of Gadobutrol. Gadobutrol was administered via a power injector at a rate of 5 mL/s followed by a 20 mL 0.9% saline flush at the same rate.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gadobutrol~0.3 mmol/kg BW (Gadavist, Gadovist, BAY86-4875)
Description: Participant received one dose of 0.3 mmol/kg BW of Gadobutrol. Gadobutrol was administered via a power injector at a rate of 5 mL/s followed by a 20 mL 0.9% saline flush at the same rate.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: OptiMARK~0.1 mmol/kg BW
Description: Participant received one dose of 0.1 mmol/kg BW of OptiMARK. OptiMARK was administered via a power injector at a rate of 2 mL/s followed by a 20 mL 0.9% saline flush at the same rate.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: OptiMARK~0.1 mmol/kg BW
Description: Participant received one dose of 0.1 mmol/kg BW of OptiMARK. OptiMARK was administered via a power injector at a rate of 2 mL/s followed by a 20 mL 0.9% saline flush at the same rate.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: OptiMARK~0.1 mmol/kg BW
Description: Participant received one dose of 0.1 mmol/kg BW of OptiMARK. OptiMARK was administered via a power injector at a rate of 2 mL/s followed by a 20 mL 0.9% saline flush at the same rate.
Study: NCT02547571

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Low residue diet

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Low residue diet
Study: NCT01618916

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY3015014
Description: Administered SC

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY3015014
Description: Administered SC

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY3015014
Description: Administered SC

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY3015014
Description: Administered SC

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Administered SC

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Administered SC
Study: NCT03212391

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Diet
Description: 52 weeks of Diet supervised by a dietician

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Diet
Description: 52 weeks of Diet supervised by a dietician

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Walking
Description: 26 weeks supervised Walking 3 times per week, followed by 26 weeks of unsupervised Walking

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Nordic Walking
Description: 26 weeks supervised Nordic Walking 3 times per week, followed by 26 weeks of unsupervised Nordic Walking
Study: NCT00553293

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: recombinant luteinizing hormone (Luveris)
Description: 75 iu/day form cycle day 6

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: recombinant follicle stimulating hormone (Gonal-f)
Description: rFSH 150 iu/day
Study: NCT04239443

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PD-1 inhibitor
Description: Intravenous administration of SHR1210 (200mg/2weeks or 200mg/3weeks)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Apatinib
Description: NSCLC and Uterine cancer will be given oral of Apatinib (250mg/d), soft tissue sarcoma will be given oral of Apatinib (500mg/d).
Study: NCT03845101

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: CBT with virtual reality exposure therapy
Description: The patients receiving the in virtuo exposure will be immersed using an Oculus Go head-mounted display, enabling viewing of 360° spherically camera recorded VR environments. The VR scenarios will thus be high-resolution 360° stereoscopic films, that are played around the viewer. For ease of use, the individual videos will be administered from an app that has been designed to be as intuitive to operate as possible. The patient will only have to put on the headset, adjust the focus and choose the desired environment by looking at it in the app. 360° video was chosen because it gives the most photorealistic visuals, while also being the cheapest to produce. The downside is that it does not allow direct user-interaction (e.g. the viewer cannot affect the environment in any way). To circumvent this, there are multiple junctions throughout the films where the actors will talk directly and unsolicited to the viewer while also allowing time for the viewer to respond.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: CBT in vivo
Description: The therapeutic intervention is manual-based cognitive-behavioral CBT group therapy adapted from the approach of Turk, Heimberg \& Magee and Graske \& Barlow with worksheets from Arendt \& Rosenberg and inspiration from Bouchard et al. The treatment will consist of 14 weekly two-hour group sessions following the manual to ensure equal and uniform treatment for every patient throughout the study. Concurrent psychopharmacological treatment is allowed in both intervention arms.
Study: NCT02433899

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: MICROSURGERY
Description: Semilunar coronally repositioned flap performed under magnification with a surgical microscope

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: MACROSURGERY
Description: Semilunar coronally repositioned flap performed without magnification

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexamethasone
Description: 8mg Dexamethasone, single dose, 1 hour before surgery

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: 8mg Dexamethasone, single dose, 1 hour before surgery

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Chlorhexidine gluconate
Description: Oral rinses with chlorhexidine gluconate, BID, for 14 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Chlorhexidine gluconate
Description: Oral rinses with chlorhexidine gluconate, BID, for 14 days

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 2.0% Mepivacaine + 1:100.000 epinephrine
Description: Regional block

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 2.0% Mepivacaine + 1:100.000 epinephrine
Description: Regional block
Study: NCT01897766

Intervention type: DRUG
Intervention: Somatropin
Description: 0.23 mg to 0.48 mg/kg/week
Study: NCT04339309

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Non-surgical periodontal treatment with interdental hygiene devices

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Non-surgical periodontal treatment without interdental hygiene devices
Study: NCT01226680

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tasocitinib
Description: 0.005% QD for 12 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tasocitinib
Description: 0.003% QD for 12 weeks

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: vehicle for Tasocitinib
Description: vehicle QD for 12 weeks
Study: NCT03904368

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Open myomectomy
Description: laparotomy then enucleation of the myoma followed by closure of the myometrial cavity

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Gonadotropins
Description: Gonadotropin stimulation of follicular growth

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Gonadotropins
Description: Gonadotropin stimulation of follicular growth

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Human chorionic gonadotropin
Description: HCG triggering of ovulation

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Human chorionic gonadotropin
Description: HCG triggering of ovulation

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Ovum pick up
Description: 34 to 36 hours after HCG triggering

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Ovum pick up
Description: 34 to 36 hours after HCG triggering

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Embryo transfer
Description: Transfer of 2 grade 1 embryo on day 2,3 or 5 from oocyte retrieval

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Embryo transfer
Description: Transfer of 2 grade 1 embryo on day 2,3 or 5 from oocyte retrieval
Study: NCT02658383

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Cleaner cookstove received after visit 2
Description: The participants will change from a traditional wood burning cookstove to a cleaner burning (wood) cookstove called the JUSTA (after visit 2).

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Cleaner cookstove received after visit 4
Description: The participants will change from a traditional wood burning cookstove to a cleaner burning (wood) cookstove called the JUSTA (after visit 4).
Study: NCT04275102

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: SPARK
Description: Prompt to complete symptom screening three times weekly via SPARK with corresponding feedback sent to healthcare providers with each completed assessment.
Study: NCT00360802

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Cognitive Behavioral Treatment
Description: Behavioral treatment to reduce pain in chronic back pain patients

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Mindfulness Based Stress Reduction
Description: Behavioral treatment to reduce pain in chronic back pain patients
Study: NCT02178527

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Foot and ankle exercises, foot orthoses, footwear provision
Description: Participants in the intervention group will receive orthoses and footwear as part of the study. The research team will train care home staff in the provision of foot and ankle exercises. The exercise protocol states that exercises will be carried out 3 times per week for 12 weeks.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Usual Care
Description: Usual general podiatry care provded by UK National Health Service
Study: NCT00655603

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Infusion of native hormones from the pancreas and gut (GLP-1)
Description: Glucose-clamps at fasting levels during infusion of hormones in different combinations.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Infusion of native hormones from the pancreas and gut (GLP-1)
Description: Glucose-clamps at fasting levels during infusion of hormones in different combinations.
Study: NCT05070468

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexamethasone 0.5mg
Description: Pregnant women with a gestational age of 38 weeks and older admitted to Labor Of Kamali Hospital, for termination of pregnancy, by accident and based on the coding done by a statistician to identify groups of users of pill A or pill B, 14 pills are used vaginally . The client and the researcher are blinded and the pharmacist delivers the dexamethasone and placebo tablets with codes A and B to the researcher.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Pregnant women with a gestational age of 38 weeks and older admitted to Labor Of Kamali Hospital, for termination of pregnancy, by accident and based on the coding done by a statistician to identify groups of users of pill A or pill B, 14 pills are used vaginally . The client and the researcher are blinded and the pharmacist delivers the dexamethasone and placebo tablets with codes A and B to the researcher.
Study: NCT02461797

Intervention type: OTHER
Group type: OTHER
Intervention: healthy controls
Description: biopsy of nasal mucosa for healthy controls

Intervention type: OTHER
Group type: OTHER
Intervention: AR patients without medication
Description: biopsy of nasal mucosa for allergic rhinitis patients without allergy medication

Intervention type: OTHER
Group type: OTHER
Intervention: AR patients with use of nasal corticoid spray
Description: biopsy of nasal mucosa for allergic rhinitis patients with use of nasal corticoid spray
Study: NCT02707042

Intervention type: DRUG
Group type: OTHER
Intervention: Amoxicillin
Description: 7-day therapeutic oral course of twice daily amoxicillin

Intervention type: DRUG
Group type: OTHER
Intervention: Azithromycin
Description: 5-day oral course of once-daily azithromycin

Intervention type: OTHER
Group type: OTHER
Intervention: Control
Description: A group of volunteers will receive no antibiotics and will serve as study controls.
Study: NCT02109016

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lucitanib
Description: Lucitanib given orally to all patients, once daily (q.d.), on a continuous schedule over 28-day cycles, in fasting conditions (at least 2 hours prior to and 2 hours after any meal), until progressive disease or unacceptable toxicity.~Starting dose is 10 mg/day and can be reduced in 2.5 mg decrements to 5 mg/day based on individual tolerability.
Study: NCT02484638

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CSL689
Description: Recombinant fusion protein, linking activated coagulation factor VII with albumin. Two dose levels (low dose, high dose) will be studied in Parts 1, 2, and 3.
Study: NCT02547571

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Low residue diet

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Low residue diet

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Low residue diet

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Low residue diet

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Early colonoscopy (stratified)
Description: Early appointments: 7:30 AM to 10h30 AM

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Early colonoscopy (stratified)
Description: Early appointments: 7:30 AM to 10h30 AM

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Early colonoscopy (stratified)
Description: Early appointments: 7:30 AM to 10h30 AM

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Early colonoscopy (stratified)
Description: Early appointments: 7:30 AM to 10h30 AM

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Early colonoscopy (stratified)
Description: Early appointments: 7:30 AM to 10h30 AM

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Early colonoscopy (stratified)
Description: Early appointments: 7:30 AM to 10h30 AM

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Later colonoscopy (stratified)
Description: Later appointments: 10:30 AM to 4:30 PM.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Later colonoscopy (stratified)
Description: Later appointments: 10:30 AM to 4:30 PM.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Later colonoscopy (stratified)
Description: Later appointments: 10:30 AM to 4:30 PM.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Later colonoscopy (stratified)
Description: Later appointments: 10:30 AM to 4:30 PM.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Later colonoscopy (stratified)
Description: Later appointments: 10:30 AM to 4:30 PM.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Later colonoscopy (stratified)
Description: Later appointments: 10:30 AM to 4:30 PM.
Study: NCT04396353

Intervention type: OTHER
Intervention: Electronic questionnaire
Description: Clinical, anthropometric, and sociodemographic variables to characterize the sample will be collected using the Google Form. The same tool will be used to collect clinical variables (outcomes), as well as to obtain data on the level of physical activity and sedentary behavior time (predictor variables) prior to SARS-CoV-2 contamination. For this, we will use the International Physical Activity Questionnaire (IPAQ).

Intervention type: OTHER
Intervention: Electronic questionnaire
Description: Clinical, anthropometric, and sociodemographic variables to characterize the sample will be collected using the Google Form. The same tool will be used to collect clinical variables (outcomes), as well as to obtain data on the level of physical activity and sedentary behavior time (predictor variables) prior to SARS-CoV-2 contamination. For this, we will use the International Physical Activity Questionnaire (IPAQ).
Study: NCT00409409

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo tablet
Description: One sublingual tablet daily during 4 months before pollen season and during pollen season
Study: NCT02049515

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IPI-145
Description: PI3K Inhibitor

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ofatumumab
Description: Monoclonal antibody
Study: NCT04280562

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Sana Pain Reliever
Description: Participants will receive the SPR device and a tablet with instructions of how to use the device and how to answer the questionnaires on the tablet mobile application. Each session with the device will last 16 minutes and run under the device's normal settings. The session consists of periods of light and sounds (beeps). Participants will be instructed to use the device each day at the end of the day prior to going to sleep and whenever they experience heightened pain during the day.

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham SPR
Description: Participants will receive the SPR device and a tablet with instructions of how to use the device and how to answer the questionnaires on the tablet mobile application. Each session with the device will last 16 minutes and run under the device's sham settings. The session consists of periods of light and sounds (beeps). Participants will be instructed to use the device each day at the end of the day prior to going to sleep and whenever they experience heightened pain during the day.
Study: NCT02869906

Intervention type: OTHER
Intervention: FFR and iFR
Description: The investigators aimed to assess the reliability of the instantaneous wave-free ratio (iFR) and fractional flow reserve (FFR) measurements in non-culprit coronary lesions during the acute and subacute phase of ST-segment elevation myocardial infarction (STEMI).
Study: NCT01114308

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Probuphine (buprenorphine implant)
Description: Implantable formulation of buprenorphine made of buprenorphine HCl/ethylene vinyl acetate, considered a drug.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo implant
Description: Implant contains ethylene vinyl acetate

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Buprenorphine
Description: sublingual buprenorphine/naloxone tablets
Study: NCT01989949

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TP-434 (Eravacycline) reconstituted and administered via an IV infusion
Study: NCT00591591

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: OxiplexTS
Description: OxiplexTS is a Frequency Domain Near-Infrared Tissue oximeter which provides absolute values of tissue oxygenation in real time. It also provides physiological quantities of oxy, deoxy and total hemoglobin concentration, which form the basis for the functional measurement of brain hemodynamics. Both the control and OSA groups will undergo standard overnight sleep study (PSG). In addition to the standard PSG, with or without Continuous Positive Airway Pressure (CPAP), we will add the OxiplexTS, allowing us to assess brain oxygenation and hemodynamics during sleep. The hemodynamic patterns of the healthy controls will be compared to the OSA sufferers. Participants with OSA who undergo PSG/CPAP will be also tested with the OxiplexTS. Their PSGs and PSG/CPAP data will be compared.